Clinical trial · no report yet · Phase 3
NCT03725059
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
- NCT03725059 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 134 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 49 | |
| Podcasts | 45 | |
| X threads | 40 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer
- Interventions
- Pembrolizumab (K); Placebo (P); Paclitaxel (X); Doxorubicin (A); Epirubicin (E); Cyclophosphamide (C); Endocrine therapy; Radiation therapy; Surgery
- Arms
- Pembrolizumab+Chemotherapy (KX/KA[E]C) · Experimental
- Placebo+Chemotherapy (PX/PA[E]C) · Placebo comparator
- Enrollment
- 1,240 (estimated)
- Primary outcomes
- Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
- Event-Free Survival (EFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 27, 2018
- Primary completion
- Jan 24, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT03725059 · updated Jul 11, 2025
Publications
linked from the registry- Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park YH, Fernandez MG, Rubovszky G, Spring L, Im SA, Hui R, Takano T, Andre F, Yasojima H, Ding Y, Jia L, Karantza V, Tryfonidis K, Bardia A. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025 Feb;31(2):442-448. doi: 10.1038/s41591-024-03415-7. Epub 2025 Jan 21. PubMed 39838117
- Schlam I, Corti C, Sammons S, Mittendorf EA, Tolaney SM. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. Expert Opin Biol Ther. 2024 Jun;24(6):511-520. doi: 10.1080/14712598.2024.2370395. Epub 2024 Jun 24. PubMed 38913933